Immunomedics and Seattle Genetics enter into US$2 B Deal for Sacituzumab Govitecan
By Natasha Piper
Pharma Deals Review: Vol 2017 Issue 3 (Table of Contents)
Published: 1 Mar-2017
DOI: 10.3833/pdr.v2017.i3.2227 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Immunomedics has entered into an exclusive global licence agreement worth up to US$2 B with Seattle Genetics...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS